Induction bortezomib in AL amyloidosis followed by high dose melphalan and autologous stem cell transplantation: A single institution retrospective study

Emma Scott, Stephen Heitner, William Dibb, Gabrielle Meyers, Stephen D. Smith, Farnoush Abar, Tibor Kovacsovics, Galit Perez-Avraham, Alex Stentz, Rachel Frires, James Dibb, Richard Maziarz

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

High dose therapy for light chain amyloidosis (AL) was performed in 31 patients at a single institution. This is a retrospective study, describing the outcomes of patients with and without cardiac involvement, patients not pre-treated as well as those that received induction chemotherapy. Bortezomib is well tolerated and results in higher overall response rates and shorter time to hematologic response.

Introduction/Background: High-dose melphalan (HDM) followed by autologous stem cell transplant (ASCT) for light chain amyloidosis (AL) was performed in 31 patients at Oregon Health and Science University between 2005 and 2012. Fifteen patients had cardiac involvement.

Patients and Methods: Patients received melphalan 200 mg/m2 or doseadjusted HDM (100-140 mg/m2) depending on high risk features. Thirteen patients proceeded directly to ASCT after diagnosis, 12 patients received a bortezomib-containing regimen, and 6 received a variety of other induction regimens.

Results: The day 100 treatment-related mortality was 9.6%. Overall hematologic (ORR) and organ response rates (OR) in the whole cohort after ASCT were 77% and 58%. ORR and OR in the bortezomib pretreated group were 92% and 75% vs. 69% and 54% in the group that received no pretreatment. The median time to maximum hematologic response after ASCT was reduced in the group that received bortezomib induction (3 vs. 14 months). Overall cardiac response rate was 60%; 100% in patients pretreated with bortezomib and 43% in those without induction treatment. With a median follow-up of 2.9 years, the 3-year progression-free and overall survival rates in the entire cohort were 66% and 73% and in those with cardiac involvement, 73% and 80%. Conclusion: We observed that bortezomib-based induction is well tolerated in patients with and without cardiac involvement and suggest that this approach be studied in prospective multi-institutional trials.

Original languageEnglish (US)
Pages (from-to)424-430.e1
JournalClinical Lymphoma, Myeloma and Leukemia
Volume14
Issue number5
DOIs
StatePublished - Oct 1 2014

Fingerprint

Melphalan
Stem Cell Transplantation
Amyloidosis
Retrospective Studies
Stem Cells
Transplants
Bortezomib
Light
Induction Chemotherapy
Disease-Free Survival
Therapeutics
Survival Rate

Keywords

  • Amyloid
  • Bortezomib induction
  • Stem cell transplantation

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology
  • Medicine(all)

Cite this

Induction bortezomib in AL amyloidosis followed by high dose melphalan and autologous stem cell transplantation : A single institution retrospective study. / Scott, Emma; Heitner, Stephen; Dibb, William; Meyers, Gabrielle; Smith, Stephen D.; Abar, Farnoush; Kovacsovics, Tibor; Perez-Avraham, Galit; Stentz, Alex; Frires, Rachel; Dibb, James; Maziarz, Richard.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 14, No. 5, 01.10.2014, p. 424-430.e1.

Research output: Contribution to journalArticle

Scott, Emma ; Heitner, Stephen ; Dibb, William ; Meyers, Gabrielle ; Smith, Stephen D. ; Abar, Farnoush ; Kovacsovics, Tibor ; Perez-Avraham, Galit ; Stentz, Alex ; Frires, Rachel ; Dibb, James ; Maziarz, Richard. / Induction bortezomib in AL amyloidosis followed by high dose melphalan and autologous stem cell transplantation : A single institution retrospective study. In: Clinical Lymphoma, Myeloma and Leukemia. 2014 ; Vol. 14, No. 5. pp. 424-430.e1.
@article{75651b87425c4ebc8402fe45c26ae80c,
title = "Induction bortezomib in AL amyloidosis followed by high dose melphalan and autologous stem cell transplantation: A single institution retrospective study",
abstract = "High dose therapy for light chain amyloidosis (AL) was performed in 31 patients at a single institution. This is a retrospective study, describing the outcomes of patients with and without cardiac involvement, patients not pre-treated as well as those that received induction chemotherapy. Bortezomib is well tolerated and results in higher overall response rates and shorter time to hematologic response.Introduction/Background: High-dose melphalan (HDM) followed by autologous stem cell transplant (ASCT) for light chain amyloidosis (AL) was performed in 31 patients at Oregon Health and Science University between 2005 and 2012. Fifteen patients had cardiac involvement.Patients and Methods: Patients received melphalan 200 mg/m2 or doseadjusted HDM (100-140 mg/m2) depending on high risk features. Thirteen patients proceeded directly to ASCT after diagnosis, 12 patients received a bortezomib-containing regimen, and 6 received a variety of other induction regimens.Results: The day 100 treatment-related mortality was 9.6{\%}. Overall hematologic (ORR) and organ response rates (OR) in the whole cohort after ASCT were 77{\%} and 58{\%}. ORR and OR in the bortezomib pretreated group were 92{\%} and 75{\%} vs. 69{\%} and 54{\%} in the group that received no pretreatment. The median time to maximum hematologic response after ASCT was reduced in the group that received bortezomib induction (3 vs. 14 months). Overall cardiac response rate was 60{\%}; 100{\%} in patients pretreated with bortezomib and 43{\%} in those without induction treatment. With a median follow-up of 2.9 years, the 3-year progression-free and overall survival rates in the entire cohort were 66{\%} and 73{\%} and in those with cardiac involvement, 73{\%} and 80{\%}. Conclusion: We observed that bortezomib-based induction is well tolerated in patients with and without cardiac involvement and suggest that this approach be studied in prospective multi-institutional trials.",
keywords = "Amyloid, Bortezomib induction, Stem cell transplantation",
author = "Emma Scott and Stephen Heitner and William Dibb and Gabrielle Meyers and Smith, {Stephen D.} and Farnoush Abar and Tibor Kovacsovics and Galit Perez-Avraham and Alex Stentz and Rachel Frires and James Dibb and Richard Maziarz",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.clml.2014.02.003",
language = "English (US)",
volume = "14",
pages = "424--430.e1",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "5",

}

TY - JOUR

T1 - Induction bortezomib in AL amyloidosis followed by high dose melphalan and autologous stem cell transplantation

T2 - A single institution retrospective study

AU - Scott, Emma

AU - Heitner, Stephen

AU - Dibb, William

AU - Meyers, Gabrielle

AU - Smith, Stephen D.

AU - Abar, Farnoush

AU - Kovacsovics, Tibor

AU - Perez-Avraham, Galit

AU - Stentz, Alex

AU - Frires, Rachel

AU - Dibb, James

AU - Maziarz, Richard

PY - 2014/10/1

Y1 - 2014/10/1

N2 - High dose therapy for light chain amyloidosis (AL) was performed in 31 patients at a single institution. This is a retrospective study, describing the outcomes of patients with and without cardiac involvement, patients not pre-treated as well as those that received induction chemotherapy. Bortezomib is well tolerated and results in higher overall response rates and shorter time to hematologic response.Introduction/Background: High-dose melphalan (HDM) followed by autologous stem cell transplant (ASCT) for light chain amyloidosis (AL) was performed in 31 patients at Oregon Health and Science University between 2005 and 2012. Fifteen patients had cardiac involvement.Patients and Methods: Patients received melphalan 200 mg/m2 or doseadjusted HDM (100-140 mg/m2) depending on high risk features. Thirteen patients proceeded directly to ASCT after diagnosis, 12 patients received a bortezomib-containing regimen, and 6 received a variety of other induction regimens.Results: The day 100 treatment-related mortality was 9.6%. Overall hematologic (ORR) and organ response rates (OR) in the whole cohort after ASCT were 77% and 58%. ORR and OR in the bortezomib pretreated group were 92% and 75% vs. 69% and 54% in the group that received no pretreatment. The median time to maximum hematologic response after ASCT was reduced in the group that received bortezomib induction (3 vs. 14 months). Overall cardiac response rate was 60%; 100% in patients pretreated with bortezomib and 43% in those without induction treatment. With a median follow-up of 2.9 years, the 3-year progression-free and overall survival rates in the entire cohort were 66% and 73% and in those with cardiac involvement, 73% and 80%. Conclusion: We observed that bortezomib-based induction is well tolerated in patients with and without cardiac involvement and suggest that this approach be studied in prospective multi-institutional trials.

AB - High dose therapy for light chain amyloidosis (AL) was performed in 31 patients at a single institution. This is a retrospective study, describing the outcomes of patients with and without cardiac involvement, patients not pre-treated as well as those that received induction chemotherapy. Bortezomib is well tolerated and results in higher overall response rates and shorter time to hematologic response.Introduction/Background: High-dose melphalan (HDM) followed by autologous stem cell transplant (ASCT) for light chain amyloidosis (AL) was performed in 31 patients at Oregon Health and Science University between 2005 and 2012. Fifteen patients had cardiac involvement.Patients and Methods: Patients received melphalan 200 mg/m2 or doseadjusted HDM (100-140 mg/m2) depending on high risk features. Thirteen patients proceeded directly to ASCT after diagnosis, 12 patients received a bortezomib-containing regimen, and 6 received a variety of other induction regimens.Results: The day 100 treatment-related mortality was 9.6%. Overall hematologic (ORR) and organ response rates (OR) in the whole cohort after ASCT were 77% and 58%. ORR and OR in the bortezomib pretreated group were 92% and 75% vs. 69% and 54% in the group that received no pretreatment. The median time to maximum hematologic response after ASCT was reduced in the group that received bortezomib induction (3 vs. 14 months). Overall cardiac response rate was 60%; 100% in patients pretreated with bortezomib and 43% in those without induction treatment. With a median follow-up of 2.9 years, the 3-year progression-free and overall survival rates in the entire cohort were 66% and 73% and in those with cardiac involvement, 73% and 80%. Conclusion: We observed that bortezomib-based induction is well tolerated in patients with and without cardiac involvement and suggest that this approach be studied in prospective multi-institutional trials.

KW - Amyloid

KW - Bortezomib induction

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=84908667921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908667921&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2014.02.003

DO - 10.1016/j.clml.2014.02.003

M3 - Article

C2 - 24650974

AN - SCOPUS:84908667921

VL - 14

SP - 424-430.e1

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 5

ER -